Leap Therapeutics, Inc. issued a press release presenting updated data from a study of DKN-01 Plus Tislelizumab and Chemotherapy in Gastric Cancer Patients at the 2023 ASCO Annual Meeting.
AI Assistant
LEAP THERAPEUTICS INC
2023
8 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.